Table 2 Mean scores of BFI and FACIT in cancer patients during the study
(A) | (B) | Â | Mean difference (A-B) | SE | 95% Confidence interval of difference | P-value | |
|---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Baseline (BFI) | End of 2nd week (BFI) | Placebo | 0.16 | 0.06 | 0.03 | 0.3 | 0.017 |
Bupropion | 0.64 | 0.16 | 0.27 | 1 | 0.002 | ||
End of 6th week (BFI) | Placebo | 0.49 | 0.1 | 0.27 | 0.7 | 0.001> | |
Bupropion | 1.8 | 0.17 | 1.8 | 2.2 | 0.001> | ||
End of 2nd week (BFI) | End of 6th week (BFI) | Placebo | 0.3 | 0.11 | 0.08 | 0.56 | 0.01 |
Bupropion | 1.16 | 0.14 | 0.8 | 1.4 | 0.001> | ||
Baseline (FACIT) | End of 2nd week (FACIT) | Placebo | - 0.57 | 0.7 | - 2.1 | 0.9 | 0.4 |
Bupropion | - 3.15 | 0.67 | - 6.4 | - 1.67 | 0.001 | ||
End of 6th week (FACIT) | Placebo | - 1.8 | 1 | - 4 | 0.3 | 0.09 | |
Bupropion | - 7 | 0.9 | - 9 | - 5 | 0.001> | ||
End of 2nd week (FACIT) | End of 6th week (FACIT) | Placebo | - 1.28 | 1.2 | - 4 | 1.4 | 0.2 |
Bupropion | - 3.9 | 0.5 | - 5 | - 2.7 | 0.001> | ||